Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ — Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; “Shattuck”) to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory … Read more